/images/ppid_59c68470-image-177018753074546188.webp)
/images/ppid_59c68470-image-177018507173534057.webp)
/images/ppid_59c68470-image-177018503245084383.webp)
/images/ppid_59c68470-image-177018502915584124.webp)
What is the story about?
Shares of Cohance Lifesciences Ltd. declined over 2% on Wednesday, February 4, after it said it received a warning letter from the US drug regulator for its formulation facility in Nacharam, Hyderabad.
The company said the US Food and Drug Administration (USFDA) had inspected the finished dosage formulations facility from August 4, 2025 to August 12, 2025.
Cohance Lifesciences said it had earlier informed the stock exchanges that the facility was classified as Official Action Indicated (OAI) and the warning letter is in continuation of the same.
"We are committed to addressing the concerns raised by the USFDA and will work with the USFDA to resolve these issues at the earliest," the company said in an exchange filing.
It also said that in the financial year 2025, the US revenues from this facility contributed less than 2% to its consolidated revenue, with related earnings before interest, tax, depreciation and amortisation (EBITDA) contribution below 1%, indicating no material impacted.
Shares of Cohance Lifesciences are trading 2% lower after the announcement at ₹373.45. The stock has declined 27.4% in the past month and 61% in the last six months.
Also Read: Five stocks, including Tata Motors CV could enter the Nifty Next 50 in March; Check potential inflows
The company said the US Food and Drug Administration (USFDA) had inspected the finished dosage formulations facility from August 4, 2025 to August 12, 2025.
Cohance Lifesciences said it had earlier informed the stock exchanges that the facility was classified as Official Action Indicated (OAI) and the warning letter is in continuation of the same.
"We are committed to addressing the concerns raised by the USFDA and will work with the USFDA to resolve these issues at the earliest," the company said in an exchange filing.
It also said that in the financial year 2025, the US revenues from this facility contributed less than 2% to its consolidated revenue, with related earnings before interest, tax, depreciation and amortisation (EBITDA) contribution below 1%, indicating no material impacted.
Shares of Cohance Lifesciences are trading 2% lower after the announcement at ₹373.45. The stock has declined 27.4% in the past month and 61% in the last six months.
Also Read: Five stocks, including Tata Motors CV could enter the Nifty Next 50 in March; Check potential inflows
